Qing Wang1. 1. Department of Molecular Cardiology, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA. wangq2@ccf.org
Abstract
PURPOSE OF REVIEW: Coronary artery disease, including its most severe complication myocardial infarction, is the leading cause of death; however, its genetic studies lag behind other diseases. Many advances have recently been made, however, and these are reviewed here. RECENT FINDINGS: Positional cloning based on genome-wide linkage analysis with large families identified the first non - lipid-related disease-causing gene, MEF2A (encoding a transcriptional factor), for coronary artery disease and myocardiaI infarction. The MEF2A mutations may account for up to 1.93% of the disease population; thus, genetic testing based on mutational analysis of MEF2A may soon be available for many coronary artery disease/myocardial infarction patients. Genome-wide association studies identified significant association for myocardiaI infarction with the LTA gene (encoding lymphotoxin-alpha), and a follow-up study found that an LTA-interacting gene, LGALS2 (encoding galectin-2), is also a susceptibility gene for myocardiaI infarction. Studies that employ genome-wide linkage scans with hundreds of small nuclear families have identified new susceptibility genes for coronary artery disease and myocardiaI infarction, including ALOX5AP (encoding 5-lipoxygenase-activating protein) associated with myocardial infarction and stroke and PDE4D (encoding phosphodiesterase 4D) for ischemic stroke. SUMMARY: Genetic studies provide new insights into the pathogenesis of coronary artery disease and myocardial infarction. Future studies will focus on identification of new disease-causing genes and susceptibility genes, exploration of the molecular mechanisms by which mutations cause coronary artery disease/myocardiaI infarction, and gene-specific therapies for patients.
PURPOSE OF REVIEW: Coronary artery disease, including its most severe complication myocardial infarction, is the leading cause of death; however, its genetic studies lag behind other diseases. Many advances have recently been made, however, and these are reviewed here. RECENT FINDINGS: Positional cloning based on genome-wide linkage analysis with large families identified the first non - lipid-related disease-causing gene, MEF2A (encoding a transcriptional factor), for coronary artery disease and myocardiaI infarction. The MEF2A mutations may account for up to 1.93% of the disease population; thus, genetic testing based on mutational analysis of MEF2A may soon be available for many coronary artery disease/myocardial infarctionpatients. Genome-wide association studies identified significant association for myocardiaI infarction with the LTA gene (encoding lymphotoxin-alpha), and a follow-up study found that an LTA-interacting gene, LGALS2 (encoding galectin-2), is also a susceptibility gene for myocardiaI infarction. Studies that employ genome-wide linkage scans with hundreds of small nuclear families have identified new susceptibility genes for coronary artery disease and myocardiaI infarction, including ALOX5AP (encoding 5-lipoxygenase-activating protein) associated with myocardial infarction and stroke and PDE4D (encoding phosphodiesterase 4D) for ischemic stroke. SUMMARY: Genetic studies provide new insights into the pathogenesis of coronary artery disease and myocardial infarction. Future studies will focus on identification of new disease-causing genes and susceptibility genes, exploration of the molecular mechanisms by which mutations cause coronary artery disease/myocardiaI infarction, and gene-specific therapies for patients.
Authors: M Bodzioch; E Orsó; J Klucken; T Langmann; A Böttcher; W Diederich; W Drobnik; S Barlage; C Büchler; M Porsch-Ozcürümez; W E Kaminski; H W Hahmann; K Oette; G Rothe; C Aslanidis; K J Lackner; G Schmitz Journal: Nat Genet Date: 1999-08 Impact factor: 38.330
Authors: A Brooks-Wilson; M Marcil; S M Clee; L H Zhang; K Roomp; M van Dam; L Yu; C Brewer; J A Collins; H O Molhuizen; O Loubser; B F Ouelette; K Fichter; K J Ashbourne-Excoffon; C W Sensen; S Scherer; S Mott; M Denis; D Martindale; J Frohlich; K Morgan; B Koop; S Pimstone; J J Kastelein; J Genest; M R Hayden Journal: Nat Genet Date: 1999-08 Impact factor: 38.330
Authors: M R Krishna Bhagavatula; Chun Fan; Gong-Qing Shen; June Cassano; Edward F Plow; Eric J Topol; Qing Wang Journal: Hum Mol Genet Date: 2004-10-20 Impact factor: 6.150
Authors: P Pajukanta; I Nuotio; J D Terwilliger; K V Porkka; K Ylitalo; J Pihlajamäki; A J Suomalainen; A C Syvänen; T Lehtimäki; J S Viikari; M Laakso; M R Taskinen; C Ehnholm; L Peltonen Journal: Nat Genet Date: 1998-04 Impact factor: 38.330
Authors: Q Chen; G E Kirsch; D Zhang; R Brugada; J Brugada; P Brugada; D Potenza; A Moya; M Borggrefe; G Breithardt; R Ortiz-Lopez; Z Wang; C Antzelevitch; R E O'Brien; E Schulze-Bahr; M T Keating; J A Towbin; Q Wang Journal: Nature Date: 1998-03-19 Impact factor: 49.962
Authors: P Pajukanta; M Cargill; L Viitanen; I Nuotio; A Kareinen; M Perola; J D Terwilliger; E Kempas; M Daly; H Lilja; J D Rioux; T Brettin; J S Viikari; T Rönnemaa; M Laakso; E S Lander; L Peltonen Journal: Am J Hum Genet Date: 2000-11-13 Impact factor: 11.043
Authors: John K Yue; Angela M Pronger; Adam R Ferguson; Nancy R Temkin; Sourabh Sharma; Jonathan Rosand; Marco D Sorani; Thomas W McAllister; Jason Barber; Ethan A Winkler; Esteban G Burchard; Donglei Hu; Hester F Lingsma; Shelly R Cooper; Ava M Puccio; David O Okonkwo; Ramon Diaz-Arrastia; Geoffrey T Manley Journal: Neurogenetics Date: 2015-01-30 Impact factor: 2.660